JP2010105968A5 - - Google Patents

Download PDF

Info

Publication number
JP2010105968A5
JP2010105968A5 JP2008281065A JP2008281065A JP2010105968A5 JP 2010105968 A5 JP2010105968 A5 JP 2010105968A5 JP 2008281065 A JP2008281065 A JP 2008281065A JP 2008281065 A JP2008281065 A JP 2008281065A JP 2010105968 A5 JP2010105968 A5 JP 2010105968A5
Authority
JP
Japan
Prior art keywords
mucosal
vaccine preparation
administration according
intranasal administration
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008281065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010105968A (ja
JP5344558B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP2008281065A external-priority patent/JP5344558B2/ja
Priority to JP2008281065A priority Critical patent/JP5344558B2/ja
Priority to EP09823688.8A priority patent/EP2345419B8/en
Priority to PCT/JP2009/068647 priority patent/WO2010050578A1/ja
Priority to ES09823688.8T priority patent/ES2624722T3/es
Priority to US13/126,357 priority patent/US20110206729A1/en
Publication of JP2010105968A publication Critical patent/JP2010105968A/ja
Publication of JP2010105968A5 publication Critical patent/JP2010105968A5/ja
Publication of JP5344558B2 publication Critical patent/JP5344558B2/ja
Application granted granted Critical
Priority to US14/478,127 priority patent/US8961983B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008281065A 2008-10-31 2008-10-31 カチオン性ナノゲルを用いる粘膜ワクチン Active JP5344558B2 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2008281065A JP5344558B2 (ja) 2008-10-31 2008-10-31 カチオン性ナノゲルを用いる粘膜ワクチン
US13/126,357 US20110206729A1 (en) 2008-10-31 2009-10-30 Mucosal vaccine using cationic nanogel
PCT/JP2009/068647 WO2010050578A1 (ja) 2008-10-31 2009-10-30 カチオン性ナノゲルを用いる粘膜ワクチン
ES09823688.8T ES2624722T3 (es) 2008-10-31 2009-10-30 Vacuna mucosa que emplea nanogel catiónico
EP09823688.8A EP2345419B8 (en) 2008-10-31 2009-10-30 Mucosal vaccine using cationic nanogel
US14/478,127 US8961983B2 (en) 2008-10-31 2014-09-05 Mucosal vaccine using cationic nanogel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008281065A JP5344558B2 (ja) 2008-10-31 2008-10-31 カチオン性ナノゲルを用いる粘膜ワクチン

Publications (3)

Publication Number Publication Date
JP2010105968A JP2010105968A (ja) 2010-05-13
JP2010105968A5 true JP2010105968A5 (enExample) 2011-11-24
JP5344558B2 JP5344558B2 (ja) 2013-11-20

Family

ID=42128937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008281065A Active JP5344558B2 (ja) 2008-10-31 2008-10-31 カチオン性ナノゲルを用いる粘膜ワクチン

Country Status (5)

Country Link
US (2) US20110206729A1 (enExample)
EP (1) EP2345419B8 (enExample)
JP (1) JP5344558B2 (enExample)
ES (1) ES2624722T3 (enExample)
WO (1) WO2010050578A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494964B1 (en) * 2007-05-14 2021-04-07 Konica Minolta Holdings, Inc. Liposome and method for producing liposome
JP5344558B2 (ja) 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
EP2490986B2 (en) 2009-10-21 2024-04-24 Revance Therapeutics, Inc. Methods and systems for purifying non-complexed botulinum neurotoxin
ES2556985T3 (es) 2011-01-11 2016-01-21 Capsugel Belgium Nv Nuevas cápsulas duras que comprenden pululano
JP6050822B2 (ja) * 2011-10-03 2016-12-21 モレインクス，エービー ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用
JPWO2013085021A1 (ja) * 2011-12-09 2015-04-27 株式会社林原 抗体産生増強用の組成物
JP6310720B2 (ja) * 2014-02-17 2018-04-11 知的財産戦略ネットワーク株式会社 肺炎球菌経鼻ワクチン
US10226529B2 (en) * 2014-06-04 2019-03-12 Osaka University Adjuvant for mucosal vaccine
WO2016081193A1 (en) * 2014-11-18 2016-05-26 Dow Global Technologies Llc Delivering a drug to a mucosal surface
US11806392B2 (en) 2016-12-03 2023-11-07 The Uab Research Foundation Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein A
WO2018189587A1 (en) 2017-04-14 2018-10-18 Capsugel Belgium Nv Process for making pullulan
CA3059527A1 (en) 2017-04-14 2018-10-18 Capsugel Belgium Nv Pullulan capsules
CN107583059B (zh) * 2017-10-31 2021-03-30 宁夏医科大学 一种可包载量子点的阳离子脂质体流感疫苗及其制备方法
CA3107263A1 (en) * 2018-08-03 2020-02-06 The University Of Tokyo Nasal vaccine that induces cell-mediated immunity
JP2020019754A (ja) * 2018-08-03 2020-02-06 国立研究開発法人農業・食品産業技術総合研究機構 ウシ乳房炎に対する粘膜ワクチン組成物
KR20230163443A (ko) 2021-03-30 2023-11-30 고쿠리츠다이가쿠호우진 도쿄다이가쿠 나노겔 피복형 백신
AU2022405521B2 (en) 2021-12-08 2026-04-02 Immunitybio, Inc. Neoepitope vaccine delivery vehicle and methods of making the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63270555A (ja) 1987-04-28 1988-11-08 日鉄鉱業株式会社 ロ−ルクラツシヤ
JPH05339169A (ja) 1992-03-03 1993-12-21 Dai Ichi Seiyaku Co Ltd 経口ワクチン
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US6656481B1 (en) * 1996-09-06 2003-12-02 Mitsubishi Chemical Corporation Vaccinal preparations
JP3416951B2 (ja) 1998-08-31 2003-06-16 順三 砂本 高純度疎水性基含有多糖類およびその製造方法
JP4599550B2 (ja) 2004-04-09 2010-12-15 国立大学法人 東京医科歯科大学 ナノゲル工学によるハイブリッドゲルの調製とバイオマテリアル応用
WO2006049032A1 (ja) 2004-11-01 2006-05-11 Tokyo Medical And Dental University ナノゲル－アパタイト複合体の調製
JP4550555B2 (ja) 2004-11-17 2010-09-22 国立大学法人 東京医科歯科大学 量子ドット（Ｑｄｏｔ）−ナノゲル複合体の調製
US20100221345A1 (en) 2006-01-18 2010-09-02 National University Corporation Tokyo Medical And Osteogenic biomaterial containing osteogenesis promoting substance and nanogel
JP2007252304A (ja) * 2006-03-24 2007-10-04 Tokyo Medical & Dental Univ ナノゲルを用いたタンパク質の細胞内導入法
JP5428017B2 (ja) * 2007-03-23 2014-02-26 国立大学法人 熊本大学 ワクチン剤
JP2008281065A (ja) 2007-05-09 2008-11-20 Nsk Ltd 玉軸受
GB0717864D0 (en) * 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
JP5344558B2 (ja) 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン

Similar Documents

Publication Publication Date Title
Dong et al. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo-and heterologous strains
CN107961374B (zh) 疫苗组合物
Riese et al. Intranasal formulations: promising strategy to deliver vaccines
Nian et al. Development of nasal vaccines and the associated challenges
JP5344558B2 (ja) カチオン性ナノゲルを用いる粘膜ワクチン
JP2010516763A5 (enExample)
MY180698A (en) Immunization protocol against the 4 dengue serotypes
JP2015535259A5 (enExample)
BRPI0212999B8 (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
TR201900418T4 (tr) Pnömokok polisakkarit konjugat aşısı.
JP2005511662A5 (enExample)
RU2016110576A (ru) Бактериальная вакцина и способы ее получения
Klein et al. Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines
Wei et al. Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms
JP6494233B2 (ja) 粘膜ワクチン組成物
JP2009514840A5 (enExample)
Nordin et al. Natural polymeric composites derived from animals, plants, and microbes for vaccine delivery and adjuvant applications: A review
Kieny et al. Research and development of new vaccines against infectious diseases
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
JP6494232B2 (ja) 粘膜ワクチン組成物
WO2018083490A3 (en) Capped oligosaccharides comprising seven or more units of 4,6-dideoxy-4-acylamido-alpha-pyranose and conjugates thereof as vaccines against infections caused by brucella organisms
WO2003008571A3 (es) Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus
JP2023514332A5 (enExample)
KR102388325B1 (ko) 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법
Li et al. Self-assembled proteinaceous nanoparticles for co-delivery of antigens and cytosine phosphoguanine (CpG) adjuvants: implications for nanovaccines